Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of padsevonil in drug-resistant focal epilepsy
NCT02625090Phase 2Terminated
- Sponsor
- UCB
- Start
- Dec 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of padsevonil in focal epilepsy, sponsored by UCB. Started Dec 2015; status: terminated.
02
Drugs
padsevonil
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT02625090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625090.